This is an interlocutory evidentiary ruling that narrows the defendants' expert case but does not decide the patent validity or infringement issues. Monitor for trial or summary judgment rulings on the '562 patent and other asserted patents protecting Lynparza.
Price Chart
Executive Summary
AstraZeneca won a Daubert motion in its ANDA litigation against generic challengers seeking to market a copy of Lynparza (olaparib). The court excluded the defendants' expert Dr. Ferraris from testifying on genetics, cancer biology, clinical trials, and cancer treatment, finding he admitted he is not an expert in those fields. This is a procedural win that strengthens AstraZeneca's patent enforcement position but does not resolve the underlying validity or infringement issues.
Court Ruling Details
Key Facts
- Court granted AstraZeneca's motion to exclude expert opinions of Dr. Dana Ferraris under Rule 702.
- Dr. Ferraris admitted he is not an expert in genetics, cancer cell biology, clinical trial interpretation, or cancer treatment.
- Dr. Ferraris may still testify on medicinal chemistry, his area of expertise.
- The ruling is in consolidated ANDA litigation over generic Lynparza (olaparib) tablets.
- The underlying patent validity and infringement claims remain unresolved.
Financial Impact
No damages awarded or financial exposure stated in the ruling.
Risk Factors
- The underlying patent case remains pending; a loss on validity or non-infringement could open the door to generic competition.
- Lynparza is a key oncology product for AstraZeneca; any adverse final ruling would have material revenue impact.
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-eb7a0fee64-AZN |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | — | awaiting T+1 | — | — |
Oct 22, 2026 5d ago | 6-K | $172.57 $171.49 | ▼ −0.63% | ▼ −0.10% | $172.06 (−0.30%) |
Oct 15, 2026 12d ago | Court Ruling | $165.41 $163.95 | ▼ −0.88% | ▼ −1.31% | $172.06 (+4.02%) |
Oct 5, 2026 21d ago | 6-K | $156.53 $158.61 | ▲ +1.33% | ▲ +0.78% | $172.06 (+9.92%) |
Oct 2, 2026 25d ago | 6-K | $156.90 $156.53 | ▼ −0.24% | ▼ −0.91% | $172.06 (+9.66%) |
Oct 2, 2026 25d ago | Court Ruling | $156.53 $158.61 | ▲ +1.33% | ▲ +0.78% | $172.06 (+9.92%) |
Oct 1, 2026 25d ago | 6-K | $157.70 $156.90 | ▼ −0.51% | ▼ −1.25% | $172.06 (+9.11%) |
Oct 1, 2026 25d ago | 6-K | $157.70 $156.90 | ▼ −0.51% | ▼ −1.25% | $172.06 (+9.11%) |
Sep 29, 2026 28d ago | 6-K | $164.21 $161.47 | ▼ −1.67% | ▼ −1.46% | $172.06 (+4.78%) |
Sep 23, 2026 4w ago | 6-K | $163.33 $164.56 | ▲ +0.75% | ▲ +0.84% | $172.06 (+5.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers